Recent Updates
Recently added Catalysts
STOK Positive Sentiment

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Tuesday, October 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Stoke Therapeutics has announced two presentations of its investigational medicine STK-002 at the upcoming American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The event is scheduled for October 9-12 in New Orleans. STK-002 aims to address the root cause of Autosomal Dominant Optic Atrophy (ADOA) by enhancing OPA1 expression.

Market Sentiment Analysis

POSITIVE FACTORS

  • Stoke Therapeutics is advancing its investigational medicine STK-002.
  • The presentations at a prominent conference highlight the company's commitment.
  • STK-002 targets the underlying cause of ADOA, potentially offering new hope.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+74%
120-day peak, hindsight
Typical move
3.5%
average across 5 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
STK-001- Single Ascending Doses
Phase 1 · Dravet Syndrome

Full Press Release Details

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 is an investigational medicine designed to target the underlying cause of Autosomal Dominant Optic Atrophy (ADOA) by increasing OPA1

Frequently Asked Questions

What is STK-002?

STK-002 is an investigational medicine developed by Stoke Therapeutics targeting Autosomal Dominant Optic Atrophy.

When is the AAO 2026 Annual Meeting?

The AAO 2026 Annual Meeting will take place from October 9-12 in New Orleans.

What condition does STK-002 aim to treat?

STK-002 is designed to treat Autosomal Dominant Optic Atrophy (ADOA).

What is the goal of STK-002?

The goal of STK-002 is to increase OPA1 expression to address the underlying cause of ADOA.

ShareAdd on Google
Tags: STOK Stoke Therapeutics STK-002 ADOA American Academy of Ophthalmology ophthalmology
Last updated: Oct 6, 2026

Biotech snapshot

Cash runway
$354M liquidity · $19M/mo burn
~17 mo
Low dilution risk
Lead asset
STK-001- Single Ascending DosesPhase 1
Dravet Syndrome →

Catalyst track record

+74%
best trade around STOK's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for STOK.

See every catalyst's timing & PoA →